**Table 2. Risk of bias assessment**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Random sequence generation (selection**  **bias)** | **Allocation concealment (selection bias)** | **Blinding of participants and personnel**  **(performance bias)**  **All outcomes** | **Blinding of outcome assessment (detection**  **bias)**  **All outcomes** | **Incomplete outcome data (attrition bias)**  **All outcomes** | **Selective reporting (reporting bias)** | **Other bias** | **Note** |
| Chopra 2014 (44) | Unclear | Unclear | Unclear | Unclear | Low | Low | High |  |
| De Lamballerie 2008 (41) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |  |
| Ahmed 2012 (45) | Low | Unclear | High | High | Low | High | Bias in the presentation of the data. | After formation of the groups the white capsule group was given  chloroquine and the red capsule group was given paracetamol |
| Ravindran 2011 (43) | Unclear | Unclear | High | High | Unclear | Unclear | Low | Only the abstract was available. Drug doses not reported. |
| Padmakumar 2009 (42) | Unclear | Unclear | High | High | Low | High | High |  |